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ABSTRACT 
Pharmaceutical analysis plays a very prominent role in quality assurance as well as quality control of bulk drugs and pharmaceutical formulations. 
Rapid increase in pharmaceutical industries and production of drug in various parts of the world has brought a rise in demand for new analytical 
techniques in the pharmaceutical industries. As a consequence, analytical method development has become the basic activity of analysis. From the 
times of yore, people were trying to find safe and sound ways to treat viral infections. In the current scenario, due to the emerging of new viruses, 
the development of drugs for their treatment is also gaining equal importance. Before launching to the market, these drugs should undergo a 
validation process. High-performance liquid chromatography (HPLC) coupled with ultraviolet (UV), Photodiode array detectors (PDA), Mass 
spectrophotometer (MS) detectors etc. is one of the fastest, safe and precise technologies used for determination and separation of pharmaceutical 
drugs, impurities and biological samples. HPLC is versatile and it takes less time for quantification of drugs as compared to old liquid 
chromatography techniques. Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC) and Efavirenz (EFV) is antiretroviral medicine used treat 
AIDS as well as chronic Hepatitis-B. It is used alone or with other HIV medications to help control HIV infection. The present review article assesses 
the published analytical methods and a variety of approach for investigation of TDF, FTC and EFV in bulk drug as well as pharmaceutical 
formulations including combinations. The present studies revealed that HPLC technique along with the spectroscopic have been most widely 
explored for the analysis. The investigatory review may provide the comprehensive details to the researchers who are working in the area of 
analytical research of TDF, FTC and EFV. 
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INTRODUCTION 
The main goal of the pharmaceutical industry is to provide drug 
products with sufficient quality, efficacy and safety. The 
development of a new drug product and its production consist of 
many pharmaceutical processes, including analytical testing. The 
analytical data generated support further decisions on how 
development should be pursued or provide information on whether 
a drug product should be released. It is important that each such 
development or production process provide credible results with 
constant quality and therefore, it needs to be controlled and, if 
necessary, continually improved. By improvement of the quality of a 
pharmaceutical process, the quality of a drug product is also 
improved. Analytical methods are among the most critical processes 
in drug product development and production. They play a key role in 
supporting other development and production processes 
throughout all stages of a drug product’s life cycle. It is essential that 
an analytical method be precise, accurate and reliable, making it 
suitable for its intended purpose [1, 2]. In most cases, the main 
working principle of an analytical method is separation of the 
analytes present in the sample. Liquid chromatography (LC) 
techniques are most commonly employed, such as HPLC or 
ultraperformance liquid chromatography (UPLC), often in reversed-
phase mode with UV absorbance detection. The purposes of analysis 
differ depending on the number, importance and relation of analytes 
that are required to be determined. Analytical methods for the assay 
of an active pharmaceutical ingredient (API) or determination of its 
related substances and degradation products are most commonly 
applied [2]. Development of a specific and robust stability-indicating 
LC method for the determination of related substances and 
degradation products is a complex process. It requires a deliberate 
forced degradation of a drug substance and/or a drug product under 
various stress conditions, such as hydrolytic, oxidative, photolytic, or 
thermal conditions, to provide stressed samples containing the 
analyte and its degradation products. The stress conditions are more 
severe than the accelerated and long-term stability conditions 
prescribed in the ICH guidelines for stability testing. An analytical 
method for determination of degradation products should be 
capable of detecting their increase during the product’s shelf life and 
the method for the assay should be capable of detecting any 
decrease in the drug substance’s content during its shelf life. Such 
methods are stability indicating [3-6].  
Recent estimates indicate that 34 million people are currently living 
with HIV/AIDS worldwide, with approximately 2.5 million new 
infections occurring annually [7]. The virus is transmitted through 
the exchange of virus containing fluids, including blood, breast milk, 
semen and genital secretions [8-10]. Routes of viral infection include 
sexual contact, injection drug use, from mother to child during 
pregnancy, childbirth, or breast-feeding, and exposure of infected 
body fluids to exposed membranes or tissue [10, 11]. Antiretroviral 
therapy (ART) is the primary modality for the treatment and 
management of the disease and can substantially reduce HIV-related 
morbidity and mortality [12-14]. ART is strongly recommended for 
all HIV-infected individuals, regardless of pretreatment CD41 T cell 
count. Furthermore, ART has shown efficacy not only in disease 
management but also in viral prevention as pre-exposure 
prophylaxis in high-risk populations [15-18]. There are currently 
more than 25 antiretroviral (ARV) agents approved for HIV 
treatment by the U. S. Food and Drug Administration (FDA) in both 
single-and multi-drug formulations [19]. Combinatorial ART 
regimens are typically required for the sustained suppression of 
viral replication and clinical benefit [20]. Currently, more than 100 
regimens exist for the treatment of HIV [21]. ARVs elicit their 
therapeutic effects through the targeted inhibition of various stages 
of the viral infection cycle. Thus, drug classes are stratified as CCR5 
antagonists, viral fusion inhibitors, nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs/NtRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), integrase strand transfer 
inhibitors (INSTIs), and protease inhibitors (PIs). Many 
combinatorial ART regimens incorporate drugs from more than one 
ARV class, and the U. S. Department of Health and Human Services 
(DHHS) has indicated recommended and alternative regimens for 
disease management [22]. In addition, new therapies are continually 
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being sought that exploit new viral targets, have activity against 
resistant viral strains, have a lower incidence of adverse effects, and 
offer convenient dosing. New agents of existing classes are currently 
in advanced stages of clinical development [23]. The growing 
demand for these agents stimulates a search for new even more 
effective drugs, but also calls for higher level of quality control of 
these therapeutic substances and preparations, so that they are in 
the highest possible degree free from any impurities that may come 
from the production process, as well as from decompositions 
products of active or auxiliary substances. Therefore, it seems 
appropriate to develop new analytical methods regarding their 
qualitative and quantitative analysis. For this aim, different 
analytical methods are used for determining anti-HIV drugs. Anti-
HIV drugs are the recent developments of drugs and there is a great 
need to review the analytical work reported so far in the literatures. 
Efforts have been made to collect the literature from 2000 up to the 
present. Analytical methods allowing the determination of TDF, FTC 
and EFV drugs in various media, such as pharmaceutical 
formulations, biological matrices and environmental samples, is 
discussed. At present, there are five major classes of ARV drugs viz. 
nucleoside reverse transcriptase inhibitor [NRTI], non-nucleoside 
reverse transcriptase inhibitor [NNRTI], Protease inhibitors [PI], 
fusion inhibitor and integrase inhibitor [IIs]. 
The first single-tablet fixed-dose combination (FDC) antiretroviral 
(ARV) has been commercially available since 2006 and is marketed 
as Atripla® [24]. A generic product has been commercially available 
in South Africa since April 2013 [25, 26] and consists of efavirenz 
(EFV), emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) 
in a ratio of 600 mg/200 mg/300 mg. TDF in this quantity is 
equivalent to 245 mg tenofovir disoproxil (TNF) and 136 mg of 
tenofovir [27]. The tablet is taken once daily for the treatment of 
HIV-1 infection [28, 29]. Once-daily FDC tablets are the simplest 
antiretroviral therapy available [30]. FDC ARV therapy is convenient 
for patients as it reduces the “pill burden” which in turn improves 
adherence to therapy [28-30]. FDC were initially indicated for 
treating HIV-positive antiretroviral naïve patients and HIV-positive 
pregnant women and those who are breastfeeding. It is now 
available to all patients on the recommendation of a physician [26]. 
Treatment with EFV, FTC and TNF is the preferred first-line therapy 
for antiretroviral naïve HIV-1-infected persons [30]. Bioequivalence 
between the dosage form containing a single molecule and the FDC 
in addition to favourable pharmacokinetics facilitates once daily 
dosing of EFV, FTC and TNF [24, 30]. 
Nucleoside reverses transcriptase inhibitors (NRTIs) 
The first generation of ARV drugs is NRTIs permitted to treat HIV 
[31]. Reverse transcriptase is an HIV enzyme that converts viral RNA 
into DNA in host CD4 cells and the process is known as reverse 
transcription. NRTIs inhibit the enzyme reverse transcriptase and 
prevent the synthesis of DNA. Without reverse transcriptase, HIV 
cannot replicate and infection cannot spread. Nucleoside analogues 
possess structural similarity with the natural building blocks of DNA 
and have to undergo phosphorylation to become active in the body. 
NRTIs are falsely chosen by reverse transcriptase to build the faulty 
DNA that denies further addition of natural nucleotides. Thus, the 
new DNA built incorrectly led to halt HIV replication [32]. Following 
are some NRTIs used for HIV therapy: Zidovudine, Didanosine, 
Stavudine, Lamivudine, Abacavir, Adefovir, Emtricitabine (FTC), 
Tenofovir disoproxil fumarate (TDF). 
Emtricitabine (FTC) 
FTC is a synthetic fluoro derivative of thiacytidine with potent 
antiviral activity approved in 2003. Chemically it is a 4-amino-5-
fluoro-1-[[2R, 5S]-2-[hydroxymethyl]-1, 3-oxathiolan-5-yl] 
pyrimidin-2-one, the solubility of which in water is 112 mg/ml with 
logP value of-1.4. FTC is a white to off white, crystalline powder [33, 
35]. FTC has an empirical formula of C8H10FN3O3S and a relative 
molecular mass of 247.2 g/mol [34, 36]. FTC contains no less than 
99.0 percent and not more than 101.0 percent of emtricitabine 
(C8H10FN3O3S), calculated with reference to the anhydrous reference 
material [34]. FTC, when combined with TDF, has shown together 
greater HIV RNA suppression compared to the combination of 
Zidovudine and Lamivudine [37, 38]. Co administration of FTC/TDF 
with antiviral drugs that eliminate through kidney by means of 
active tubular discharge may enhance plasma TDF or FTC 
concentrations and/or those of simultaneously given drugs [39]. 
FTC undergoes phosphorylation to form active FTC triphosphates 
metabolite using cellular kinase enzymes. FTC and phosphorylated 
metabolite give varying pharmacokinetic results [40]. The molecules 
mimic normal nucleos(t)ides that are incorporated into DNA at the 
3’ terminus. However FTC and TNF lack the 3’-OH and their 
incorporation at the 3’ terminus of the DNA therefore terminates 
chain elongation by preventing incorporation of additional 
nucleotides [28, 41, 42]. TDF diphosphate and FTC 5’-triphosphate 
are weak inhibitors of α, β, ϒ cellular DNA polymerases and FTC 5’-
triphosphate weakly inhibits DNA polymerase ε [28]. The 
combination of TNF and FTC has been the preferred NRTI regimen 
since 2003 since approval by FDA [30]. A single-tablet combination 
has been approved by the FDA and more recently by the Medicines 
Control Council (MCC) of South Africa for pre-exposure prophylaxis 
(PrEP) although it is not widely used clinically [43, 44]. The HIV-1 
reverse transcriptase (RT) mutation K65R is a common multi-drug 
resistance mutation that confers resistance to NRTI including TNF 
and FTC [11, 42, 45, 46] and this mutation may be responsible for 
cross-resistance between different NRTI [42, 46]. Cases of acute 
renal failure and Fanconi syndrome (FS) have been reported in 
patients treated with TNF [47] although clinically important renal 
toxicity is rare [48]. FTC and TNF undergo limited systemic 
metabolism [49]. 
Tenofovir disoproxil fumarate (TDF)  
TDF is the acyclic nucleotide analogue of adenosine monophosphate 
approved for HIV treatment in 2004 [50]. Chemically, it is an [[2R]-
1-[6-aminopurin-9-yl]propan-2-yl]oxymethyl phosphonic acid, the 
solubility of which in water is 13.4 mg/ml at 25 °C with a logP value 
of-1.6. TDF has an empirical formula of C19H30N5O10P, C4H4O4 and a 
relative molar mass of 635.5 g/mol. It occurs as a white to almost 
white crystalline powder [51-53]. TDF contains no less than 98.5 
percent and not more than 101.0 percent of TDF (C19H30N5O10P, 
C4H4O4), calculated with reference to an anhydrous reference 
material [52]. TDF refers to the solid/raw material whereas TNF 
refers to TDF in solution and tenofovir peaks in chromatograms. 
TDF is phosphorylated twice to the active diphosphate form. High fat 
meal increases the bioavailability of TDF and remains unaffected by 
normal meal [54]. As TDF is eliminated through the kidney and is 
not a substrate for CYP45, its dosage regimen needs to be modified 
in renal complications [55, 56]. Gervasoni et al. showed that HIV-
infected females with diminished body weight are in danger to be 
exposed to elevated TDF plasma trough concentrations, eventually 
bringing about a huge threat to produce long-term TDF 
complications [55].  
Non-nucleoside reverse transcriptase inhibitor [NNRTI] 
NNRTIs restrain the process of viral DNA synthesis by directly 
binding to the hydrophobic pocket of reverse transcriptase enzyme 
[31]. Unlike NRTIs, which must be phosphorylated to prevent HIV 
from infecting the cell, NNRTIs are active in the form administered. 
NNRTIs are classified as 1st generation and 2nd generation NNRTIs. 
1st generation NNRTIs include Nevirapine and Efavirenz [EFV] and 
2nd generation NNRTIs are Etravirine and Rilpivirine. HIV-2 is 
naturally resistant to NNRTIs. 
Efavirenz (EFV)  
EFV is a benzoxazin analogue approved by FDA in 1998 for the 
treatment of patients infected with HIV [57]. Chemically, it is an 
[4S]-6-chloro4-[2-cyclopropylethynyl]-4-[trifluoromethyl]-1H3,1-
benzoxazin-2-one and occurs as a white to slightly pink crystalline 
powder [58-60]. The empirical formula for EFV is C14H9ClF3NO2 and 
the relative molar mass is 315.7g/mol [58, 60, 61]. EFV contains no 
less than 97.0 percent and not more than 103.0 percent of 
C14H9ClF3NO2 calculated with reference to the anhydrous reference 
material [58]. The solubility of which in water is 0.093 mg/l at 25 °C 
with logP value of 4.6. The dosing of EFV is once-daily due to its long 
half-life. EFV is usually preferred to treat HIV patients co-infected 
with tuberculosis [TB]. Both the diseases are life-threatening and 
treatment becomes very difficult due to drug-drug interactions 
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between EFV and rifampicin [62, 63]. Side effects of EFV are found to 
be associated with the EFV plasma concentration. Various side 
effects are associated with high and low plasma levels of EFV 
particularly in HIV-TB co-infected patients for which TDM studies 
become necessary. EFV levels are directly correlated with optimum 
therapeutic output and central nervous system side effects. 
Therefore, TDM of EFV in clinical practice is essential for optimum 
therapeutic output, especially in HIV-TB co-infected patients who 
are under treatment with the combination of EFV and rifampicin. On 
the other hand, EFV possesses high protein binding property [>99%] 
and thus gets penetrated into male genital tract through blood. High 
penetration in male genital tract makes it an important candidate to 
study its concentration for prophylaxis use. HIV replication took 
place inside the cell, so ARV drugs have to enter the cells at an 
adequate concentration to restrain viral replication. Subsequently, 
studying intracellular drug concentration is a valuable tool to 
ascertain effective levels of ARVs in target cells mainly in virological 
failure regardless of efficient plasma level concentrations.  
Dissociation constant (pKa)  
EFV is a weak acid with a pKa of 10.2. It is therefore ionised at high 
pH, at which the carbonate moiety undergoes deprotonation to form 
a negatively charged species. The trifluoromethyl and ethylene 
moieties are most likely responsible for the lowering of the pKa [64, 
65]. The pKa of FTC and TNF are 2.65 and 3.75 respectively [35, 36, 
66]. EFV is a weak acid whereas FTC and TNF are weak bases. 
Solubility 
EFV is practically insoluble in water (9.0μg/ml) but is freely soluble in 
methanol [14, 31, 38, 39]. FTC is freely soluble in methanol and water 
(112 mg/ml) and is practically insoluble in dichloromethane R [34-36, 
58]. TNF has a solubility of 13.4 mg/ml in distilled water at 25 °C [51]. 
Biopharmaceutical classification system (BCS) 
The BCS provides a framework to classify molecules into categories 
based on their aqueous solubility and membrane permeability. Class 1 
drugs have high solubility and high permeability, class 2 drugs low 
solubility and high permeability, class 3 drugs high solubility and low 
permeability and class 4 drugs low solubility and low permeability. EFV 
has low aqueous solubility and high intestinal permeability and is 
classified as a Class 2 molecule. FTC has high aqueous solubility and high 
intestinal permeability and is classified as a Class 1 molecule. TNF, the 
form of tenofovir that is aborbed, has high aqueous solubility and low 
intestinal permeability and is classified as a Class 3 molecule [67, 68]. 
Melting range 
EFV melts within the range of 139-141 °C [69]. FTC melts within the 
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Fig. 1: Chemical structure of (A) Emtricitabine, (B) Tenofovir, (C) Efavirenz, reported analytical methods for TDF, FTC and EFV 
 
Spectrophotometric methods 
Many analytical methods involving spectroscopic analysis of the 
drug individually and as multicomponent samples have been 
reported. These methods include a simultaneous equation method, 
derivative spectrophotometric method, absorption ratio and a 
method based on Q analysis.  
Chromatographic method 
Liquid chromatographic analysis for the determination of TDF, FTC 
and EFV individually and in combination has been reported covering 
different phases of analytical research viz; profiling of impurities, 
stability indicating analytical methods, bioanalytical method 
development in different biological fluids to determine the 
concentration of TDF, FTC and EFV in human serum and to 
determine simultaneously in synthetic mixture or combination 
dosage form. 
Stability indicating method 
Stability indicating method is used to check drug stability under 
different conditions. Here, TDF, FTC and EFV are studied by RP-
HPLC and UPLC for stability studies. 
 
Table 1: RP-HPLC/UPLC methods for determination of TDF, FTC and EFV 
S. No. Name of drug/formulation 
/biological fluid 
Column Mobile phase composition Detection 
(nm) 
Ref. 
1 FTC-Tablet Peerless basic C18 (50 mm x 4.6 mm, 
3μm) 
Buffer (pH 3.0): methanol-90:10% (v/v) 280 nm 72 
2 FTC-Nanoparticles Phenomenex C18 (250 mm × 4.6 mm, 
5𝜇m) 
40 mmol phosphate buffer (pH 6.8), methanol 
and 2% acetonitrile (83: 15: 2, v/v/v) 
280 nm 73 
3 FTC-Tablet Phenomenex C18 (250 mm × 4.6 mm, 
5𝜇m) 
10 mmol phosphate buffer (pH 6.8) methanol-
2% acetic acid (73: 25: 2, v/v/v) 
280 nm 74 
4 FTC-Capsule Luna RP-18(2),250X4.6 mm, 5 µm Buffer: acetonitrile (85:15 %v/v) 280 nm 75 
5 FTC-Capsule Phenomenex (Torrance, CA) C8 250× 
4.6 mm 
0.03M Phosphate buffer (pH 4.86±0.02): 
acetonitrile: methanol (40:20:40 v/v/v) 
280 nm 76 
6 FTC/TDF/Elvitegravir/Cobici
stat-Tablet 
Inertsil ODS 3V C18 (250 mm×4.6 mm, 
5 μm, 100Å) 
A =KH2PO4 (0.02M) pH 2.5, B= acetonitrile 240 nm 77 
7 FTC/TDF-Tablet Hypersil, 250 X 4.6 mm, 5µ Buffer (pH 3.7): acetonitrile 60:40 (v/v) - 78 
8 FTC/TDF/Rilpivirine-Tablet Inertsil C18 (150x4.6 mm, 5 µm) 0.1N Phosphate buffer(pH: 4): acetonitrile 
(40:60v/v) 
275 nm 79 
9 FTC/TDF-Tablet Inspire C18 (150×4.6 mm) 5.0 µm Buffer (pH 2.5): methanol (30:70 v/v) 272 nm 80 
10 FTC/TDF-Tablet Inspire C18 (4.6×250 mm) 5 µm Mixed buffer (KH2PO4 and K2HPO4) pH 3: ACN 
(30:70v/v) 
273 nm 81 
11 FTC/TDF/Rilpivirine–Tablet Kromasil C18 (250 mm × 4.6 mm, 5µ) 0.01N Potassium dihydrogen phosphate and 
acetonitrile 65:35 (v/v/) 
279 nm 82 
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Atlantis C18 (100×4.6 mm, 5 μm) Gradient mixture of 0.1% trifluoroacetic acid 
and acetonitrile 
240 nm 83 
13 FTC/TDF–Plasma Hypersil C18 (250 mm×4.0 mm, 5 μm) sodium dihydrogen orthophosphate buffer (pH 





14 FTC/TDF/Rilpivirine Thermo Hypersil ODS C18 (150×4.6 
mm, 5µ) 
Acetonitrile and Phosphate buffer pH 3 (60:40) 260 nm 85 
15 FTC/TDF-Tablet DIKMA (50 x 2.1 mm, 1.7µ) Phosphate buffer (pH 5.6) and methanol 60:40  240 nm 86 
16 FTC/TDF-Tablet Hypersil TM BDS C18 120A (250 × 4.60 
mm, 5µ) 
Methonal and phosphate buffer pH 2.5 (65:35 
% v/v) 
261 nm 87 
17 FTC/TDF/Bictegravir-Tablet  Zodiac C18 150x4.6 mm, 5µ Buffer and Acetonitrie (55:45 v/v) 272 nm 88 
18 FTC/TDF-Tablet Phenomenex-Luna C18 (25 cm x 4.60 
mm, 5 µm) 
10 mmol phosphate buffer (pH 6.8): 
acetonitrile; 40: 60 (v/v) 
260 nm 89 
19 FTC/TDF/Elvitegravir/Cobici
stat-Tablet 
ODS (250 × 4.6 mm, 5 µm)  A= (potassium dihydrogen orthophosphate, pH 
2.5)  
B= (acetonitrile) 55:45% v/v  
250 nm 90 
20 FTC/TDF-Tablet Phenomenax Luna C18 (150 mm x 4.6 
mm, 5 µm) 
Acetonitrile: methanol: water 30:50:20 (v/v) 258 nm 91 
21 FTC/TDF-Tablet BEH C18 (100 mm × 2.1, 1.8 µm) 0.68% potassium dihydrogen orthophosphate 
buffer of pH = 6 and methanol 45:55 v/v 
261 nm 92 
22 FTC/TDF-Tablet Luna C18 (25 cm x 4.60 mm, 5 µm) Acetonitrile: potassium dihydrogen phosphate 
buffer (pH 3.0±0.05): triethylamine 
70:30:0.5(v/v)  
260 nm 93 
23 FTC/TDF-Tablet Promosil C18, (250 mm, 4.6 mm, 5 µm) Methanol: Phosphate cushion 68:32 % v/v. 259 nm 94 
24 FTC/TDF-Tablet Inertsil ODS C18 (250 mm x 4.6 mm, 5 
µm) 
0.1% triflouro acetic acid (TFA) buffer and 
methanol 39:61 (v/v) 
261 nm 95 
25 FTC/TDF/Cobicistat/Elvitegr
avir-Tablet 
Kromasil C18 (250×4.6 mm, 5 µm) Orthophosphoric acid buffer: acetonitrile 
(55:45 %v/v) 
240 nm 96 
26 FTC/TDF-Tablet Phenomenax Luna C18 (250 mm x 4.6 
mm, 5 µm) 
Methanol: phosphate buffer pH-3 (70:30 v/v) 258 nm 97 
27 FTC/TDF/Dolutegravir-
Tablet  
Phenomenex kinetex Biphenyl 
250x4.6 mm, 5 µm 
A= ammonium acetate (10 mmol) pH 3.0, B= 
Acetonitrile, ammonium acetate (10 mmol) pH 
3.0 and methanol 70:15:15%v/v/v  
260 nm 98 
28 FTC/TDF/Cobicistat, 
Elvitegravir-Tablet 
Kromasil C18 (250 mm x 4.6 mm x5 
µm) 
0.01N KH2PO4(pH 2.5) and acetonitrile 
(43:57v/v) 
254 nm 99 
29 FTC/TDF/Cobicistat, 
Elvitegravir-Tablet 
Hypersil BDS C18 250x4.6 mm, 5 µ, 
100A. 
0.05M Phosphate buffer pH 3.0 and 
acetonitrile 95:5  
240 nm 100 
30 FTC/TDF/Rilpivirine-Tablet Agilent C18 (250 × 4.6 mm, 5 μm) 0.1%Formic acid: acetonitrile (65:35%, v/v) 250 nm 101 
31 TDF-Tablet Phenomenex Luna C18 (250 x 4.6 mm x 
5 μm) 
Orthophosphoric acid (pH 3.0): acetonitrile: 
aethanol (40:50:10% v/v)  
254 nm 102 
32 TDF/lamivudine-Tablet HypersilTM BDS C18 120A (250×4.60 
mm, 5µ) 
Acetonitrile and phosphate buffer pH 3.5 
(80:20% v/v) 
260 nm 103 
33 TDF/lamivudine-Tablet Inertsil C18 column (15 cm x 4.6 mm, 5 
µm) 
6.5 mmol Phosphate buffer pH 2.5 and 
acetonitrile (50:50 v/v) 
260 nm 104 
34 TDF-Tablet Acquity UPLC BEH C18 (1.7 µm, 1 mm 
X 50 mm) 
0.1% Formic acid and acetonitrile  - 105 
35 TDF/lamivudine Waters X-terra RPC18 (150 x 4.6 mm, 
3.5 µm) 
A= (ammonium acetate buffer, pH 5.0±0.05) 
and B= (methanol and ammonium acetate 
buffer 20:80) 
260 nm 106 
36 TDF/lamivudine-Tablet C18 (Inertsil ODS 3V, 250 mm x 4.6 
mm; 5µ) 
Phosphate buffer (pH3.5) and acetonitrile 
55:45 v/v 
264 nm 107 
37 TDF-Tablet HiQ Sil C18HS (250 mm×4.6 mm, 5.0 
µm) 
Methanol: water (60:40, v/v) 260 nm 108 
38 EFV-Tablet Welchrom C18 (4.6 X 250 mm, 5 µm) 10 mmol Phosphate buffer (pH3.0): 
acetonitrile (50:50 v/v) 
246 nm 109 
39 EFV-Plasma Waters X-Terra Shield, C18 50 x 4.6 
mm, 3.5 μm 
Phosphate buffer pH 3.5 and acetonitrile 260 nm 110 
40 EFV/Lamivudine/Stavudine-
Tablet  
Inertsil ODS C18(4.6 X 250 mm, 5.0μm) Phosphate Buffer (pH 4): methanol 30:70 v/v 254 nm 111 
41 EFV-Tablet C18 250 x 4 mm (10 µm)  ACN: water: 85% H3PO4 (70:30:0.1) 252 nm 112 
42 EFV-Tablet Develosil ODS HG-5 RP 150 mm × 4.6 
mm 5 µm 
Phosphate buffer (pH 3.1) and acetronitrile 
40:60. 
249 nm 113 
43 EFV-Tablet Waters XBridge (4.6× 250 mm, 5 µm) Ammonium format buffer (pH 5): ACN (28:72 
v/v) 
247 nm 114 
44 EFV/Lamivudine-Tablet Acquity UPLC BEH Shield RP18 (50 × 3 
mm, 1.7 µm) 
10% acetonitrile in methanol and 10 mmol 
phosphate buffer (pH 4.0) 
254 nm 115 
45 EFV/TDF/lamivudine-Tablet Kromasil C18 analytical column (150 × 
4.6 mm, 5 μm) 
10 mmol phosphate buffer (pH 5.0) and 
methanol (30:70) 
254 nm 116 
46 EFV/TDF/lamivudine-Plasma Luna C18 (250 × 4.6 mm, 5µ) A: Water with 0.1% (THF); B: acetonitrile with 
0.1% THF 
254 nm 117 
47 EFV/TDF/lamivudine-Tablet SHISEIDO C18 (250 x 4.6 mm, 5µ) Acetonitrile: 50 mmol phosphate buffer (pH 
5.0)  
256 nm 118 
48 FTC/TDF/EFV-Tablet Zorbax SB-Phenyl, (250 mm X 4.6 
mm), 5 µm 
A: Buffer pH 3.7 B: methanol, acetonitrile and 
tetrahydrofuran (50: 50: 2 v/v/v)  
265 nm 119 
49 FTC/TDF/EFV-Tablet Inertsil ODS 3V (250 x 4.6 mm, 5µ) A: 0.02M Sodium dihydrogen orthophosphate 
monohydrate B: methanol and water (85:15) 
265 nm 120 
50 FTC/TDF/EFV-Plasma Chromolith Performance RP-18e (100 
× 4.6 mm) 
A: (0.1% formic acid), B: acetonitrile - 121 
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51 FTC/TDF/EFV Acquity UPLC BEH m) cµPhenyl 
(2.1×100 mm, 1.7 
A: (Buffer, 1.0 ml of TEA in 1000 ml of water 
pH 4.0±0.05) and B: (buffer: acetonitrile 
(20:80, v/v) 
265 nm 122 
52 FTC/TDF/EFV-Tablet Phenomenex C8 (250 mm ×4.6 mm, 5 
µm) 
Buffer pH: 7.0 acetonitrile and methanol 
(40:40:20 v/v) 
262 nm 123 
53 FTC/TDF/EFV-Tablet Kromosil C18 100 x 4.6,3.5µ 0.1M ortho phosphoric acid buffer and 
acetonitrile in 60:40 v/v 
265 nm 124 
54 FTC/TDF/EFV-Tablet XTerra symmetry C18 (4.6 x 150 mm, 
3.5 µm) 
Di hydrogen sulphate: methanol 270 nm 125 
55 FTC/TDF/EFV-Tablet Zorbax C8 column (150 mm x 4.6 mm, 
5 µm)  
Buffer pH 2.4±0.02 and acetonitrile 70:30 v/v 252 nm 126 
56 FTC/TDF/EFV-Tablet Acquity 50 mm×m 2.1 µUPLC BEH 
Phenyl 1.7 
A: 0.2% TEA in water pH 6.5±0.05, B: methanol 
and acetonitrile 50: 50 (v/v) 
260 nm 127 
57 FTC/TDF/EFV-Tablet Hypersil BDS C18 column (25 cm × 4.6 
mm 5 µm) 
Acetonitrile, phosphate buffer and water 280 nm 128 
58 FTC/TDF/EFV-Tablet Thermosil C18 (100*4.6 mm, 5µ) Methanol and Triethylamine (pH 7) (70:30 
V/V  
260 nm 129 
59 FTC/TDF/EFV-Tablet Inertsil ODS 3 V C18 (150 mm × 4.6 
mm 5 𝜇m)  
Phosphate buffer (pH 3.5): acetonitrile (70: 30 
v/v)  
256 nm 130 
60 FTC/TDF/EFV-Tablet Zorbax SB CN, (250 × 4.6 mm, 5 µm) A: methanol, B: buffer at pH 4.5 260 nm 131 
61 FTC/TDF/EFV-Tablet HSS C18 (100 × 3 mm, 1.7 µ) 0.01 N Phosphate buffer (pH 4.5) and 
acetonitrile (40:60, v/v) 
265 nm 132 
62 FTC/TDF/EFV-Tablet Inerstil ODS C18 250x4.6 mm, 5 µm A: Buffer (0.05% Trifluro acetic acid in water) 
B: methanol  
262 nm 133 
63 FTC/TDF-Tablet C18 (250 x 4.6 mm) Methanol: distill water 60:40 v/v (pH-3) 260 nm 134 
64 FTC/TDF/Rilpivirine-Tablet Inertsil ODS 3V C18 (250 mm×4.6 mm, 
5 µm), 
0.01M phosphate buffer (pH 4) and 
acetonitrile (30:70 v/v) 
265 nm 135 
65 FTC/TDF-Tablet Hi Q C18 W (150 mm: 4.6 mm, 5 μ) Buffer, methanol and acetonitrile (40: 50: 10) 265, 278 
nm 
136 
66 FTC/TDF/Rilpivirine-Tablet Acquity BEH C18 (50 x 2.1 mm, 1.7 µm) Acetonitrile and phosphate buffer (pH 
3)55:45(v/v).  
261 nm 137 
67 FTC/TDF/Lamivudine-
Plasma 
ACE 5 CN (150 mm × 4.6 mm, 5 µm) 0.5% Formic acid in water and acetonitrile 
(55:45, v/v) 
- 138 
68 FTC/TDF-Tablet Premsil C18 (250 mm×4.6 mm, 5 μm) Methanol: water (70:30 v/v) pH 3 273 nm 139 
69 FTC/TDF-Tablet Zorbax SB-C8 5 μm, 4.6 × 250 mm 50 mmol Phosphate buffer (pH 6.0)-




70 FTC RP C18 (25 cm×4.6 mm), 5 μm ACN, phosphate buffer (pH 4.4), and water 280 nm 141 
71 FTC/TDF-Plasma Synergi Polar-RP, 2.0 mm×150 mm, 3% Acetonitrile/1% acetic acid, aq.) - 142 
72 FTC/TDF-Plasma Chromolith Speed Rod RPC18 (50 
mm×4.6 mm) 
Methanol,acetonitrile and ammonium acetate 
(pH 3.0, 40 mmol) (20:80, v/v) 
- 143 
73 FTC/TDF-seminal plasma Atlantis T3 C18 (2.1 × 100 mm, 3 µm) A: Deionized water with 0.05% formic acid, B: 
methanol with 0.05% formic acid 
- 144 
74 FTC/TDF-Tablet Agilent TC-C18 5 mm, 4.6´250 mm Methanol and phosphate buffer (30:70 v/v, pH 
4) 
261 nm 145 
75 FTC/TDF-Tablet Inertsil ODS C18, (4.6 × 250 mm, 5 µm) Buffer: Acetonitrile (80:20) 259 nm 146 
76 FTC/TDF/EFV-Tablet Hypersil BDS C18, 250x4.6 mm, 5 μm Acetonitrile and 0.03M KH2PO4 (pH 3.2) 60:40 
v/v  
260 nm 147 
 
Table 2: Spectrophotometric methods used for determination of TDF, FTC and EFV alone and in combined dosage form 
S. No. Name of drug Sample matrix Method Detection (nm) Ref. 
1 EFV Tablet Zero order 247 148 
2 TDF Tablet Zero order 260 149 
3 EFV/TDF/Lamivudine Tablet Simultaneous equation 247, 260, 272 nm 150 
4 FTC Tablet Zero order and area under curve  280 nm, 272-286 nm 151 
5 TDF Tablet Zero order 260 nm 152 
6 EFV/TDF/Lamivudine Tablet Zero order 247, 260, 272 nm 153 
7 FTC/TDF Bulk Simultaneous equation, Q–
absorbance ratio method 
(1)280 nm, 260 nm (2) 251,237 nm 154 
8 FTC/TDF Tablet Simultaneous equation eethod 282,261 nm 155 
9 FTC/TDF Tablet Simultaneous Equation Method 281, 210 nm 156 
10 FTC/TDF/EFV Tablet Simultaneous equation method 260, 241, 240 nm 157 
11 FTC/TDF/Cobicistat/Elvitegravir Tablet Simultaneous equation method 283, 259, 240, 258 nm 158 
12 FTC Tablet Zero order, first order derivative 241.1 and 232.7 nm 159 
13 FTC/TDF Tablet Least square, first order, area under 
curve 
281,260.5 nm; 234.5, 281 nm; 278-
283 nm,258-262 nm 
160 
14 TDF Tablet Zero order, first order 260 nm, 273 nm 161 
15 EFV/TDF/Lamivudine Tablet Simultaneous equation method, 
multicomponent analysis and 
derivative spectroscopy method  
247, 259 and 272 nm 162 
16 EFV/TDF/Rilpivirine Tablet Simultaneous equation method 240.8, 257.6, and 305.6 nm 163 
17 EFV/TDF Tablet Simultaneous equation and 
Absorbance ratio method 
250, 274 nm; 255, 274 nm;  164 
18 EFV/TDF Tablet Ratio derivative spectra, first-order, 
absorption corrected method 
271.07 and 302.17 nm; 224.38 and 
306.88 nm 
165 
19 EFV/TDF Tablet Zero order 298 nm 166 
20 TDF/Lamivudine Tablet Simultaneous equation method 271and 261 nm 167 
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Table 3: HPTLC methods for determination of TDF, FTC and EFV 
S. No. Name of drug  Formulation  Stationary phase 
plates  
Mobile phase composition Rf Ref. 
1 EFV/Lamivudine Tablet silica gel 60G 
F254 
Ethyl acetate: methanol: 
formic acid 7.0:2.5:0.5 (v/v) 
Lamivudine= 0.57±0.02 
EFV= 0.72±0.01  
168 
2 FTC/TDF/EFV Tablet silica gel 60F 254 Chloroform: methanol 
(90:10) 
FTC =0.15, TDF =0.34, EFV 
=0.55 
169 
3 FTC/TDF/Rilpivirin Tablet silica gel 60 F254 Methanol: toluene: 
ethylacetate: ammonia 
(1.5:5.5:1.5:0.1 v/v/v/v) 
Rilpivirin= 0.59, FTC= 
=0.29, TDF= 0.41  
170 
4 TDF/Lamivudine Tablet silica gel 60 F254, 
(20 × 10 cm) 
Chloroform: methanol: 
toluene (8: 2: 2, v/v/v) 
TDF= 0.51, Lamivudine= 
0.27 
171 
5 EFV Tablet silica gel 60 F 254 Toluene: ethyl acetate: formic 
acid (10: 3: 1 v/v) 
0.41±0.01 172 
6 EFV Plasma silica gel 60F254 Dichloromethane: methanol 
(5:0.3 v/v) 
0.69±0.01 173 
7 TDF Tablet silica gel GF 
aluminum 
Ethyl acetate: methanol: 
formic acid(7:2.5:0.5 %v/v) 
0.78 174 
8 FTC/TDF/Rilpivirin Tablet silica gel 60 F254 Chloroform: ethyl acetate: 
methanol: glacial acetic acid 
(5:2:1:0.1 v/v/v/v) 





The present review discussed about different analytical approach 
employed for the assessment of TDF, FTC and EFV. Profuse 
examinations have been accomplished including, Bio-analytical, HPLC, 
UPLC, HPTLC, UV/Vis-Spectroscopy, LC-MS, LC-ESI-MS etc. for 
evaluation of TDF, FTC and EFV in bulk and in its combination with 
other drugs from pharmaceutical formulations and also biological 
fluids. Liquid chromatography with UV detection has been found to be 
most studied for estimation of TDF, FTC and EFV in bulk as well as 
pharmaceutical dosage forms, while hyphenated LS-MS, LSMS/MS 
methods reported for determination of TDF, FTC and EFV and its 
metabolite in plasma and other biological fluids. Few chromatography 
approaches like HPTLC and Stability-indicating HPLC, UPLC and 
HPTLC are also reported. Few simple UV-Spectrophometric methods 
may be used for routine analysis of TDF, FTC and EFV alone and in 
combination with other drugs. These compiled data may of use for 
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